Latest filing published 22 Sept 2022 for ExpreS2ion Biotech Holding AB (EXPRS2), €13k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -63.2%Entry 180.74 · Close at T+365 66.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Mette Thorn: trading record in brief
All filings by Mette Thorn on record concern ExpreS2ion Biotech Holding AB (EXPRS2). In total, 3 filings cover trades dated from 9 May 2022 to 20 September 2022.
Both buying and selling appear: 1 purchase worth €937, against 1 sale worth €13k. Netting one side against the other leaves €12k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Most recently, on 22 September 2022, the filings show an open-market sale worth €13k in ExpreS2ion Biotech Holding AB (EXPRS2). The latest purchase dates back some time: it was published 1,643 days ago, on 9 May 2022. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 2 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Companies and markets linked to Mette Thorn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,000 shares@ SEK 12.106567.7% of flowAktieISIN SE0008348262FI:csv-802642ea51da5d09a3af
- 12,000 shares@ SEK 4.8127.5% of flowAktieISIN SE0008348262FI:csv-b4cc76a72522fffa42a9
- 800 shares@ SEK 12.504.7% of flowAktieISIN SE0008348262FI:csv-94c4c0622cf23c489934Canonical exit: 7 Aug 2022 (T+90)
3 of 3 declarations